Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 9:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 6,975 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal and Urinary Disorders Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

NCT03643965
View directory record Official record
Conditions
Primary IgA Nephropathy
Interventions
Nefecon, Placebo oral capsule
Drug
Lead sponsor
Calliditas Therapeutics AB
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 7, 2026, 9:59 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Sprix for Postoperative Pain Control Following Gynecologic Surgery

NCT04444830
View directory record Official record
Conditions
Post Operative Pain Control, Narcotic Use, Pelvic Organ Prolapse, Urinary Incontinence , Stress, Surgery
Interventions
Sprix
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 7, 2026, 9:59 PM EDT
Terminated Phase 4 Interventional

Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis

NCT00062699
View directory record Official record
Conditions
End-Stage Kidney Disease
Interventions
Zemplar (paricalcitol injection), Calcijex
Drug
Lead sponsor
Abbott
Industry
Eligibility
20 Years and older
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
60
States / cities
Tuscaloosa, Alabama • Inglewood, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2006 · Synced Oct 7, 2026, 9:59 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

NCT00945009
View directory record Official record
Conditions
Adult Kidney Wilms Tumor, Beckwith-Wiedemann Syndrome, Childhood Kidney Wilms Tumor, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Rhabdoid Tumor of the Kidney, Stage I Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor, Stage V Kidney Wilms Tumor
Interventions
Dactinomycin, Doxorubicin Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery, Vincristine Sulfate
Biological · Drug · Radiation + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
146
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 7, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

Daratumumab in Treatment of PGNMID and C3 GN

NCT03095118
View directory record Official record
Conditions
Membranoproliferative Glomerulonephritis
Interventions
Daratumumab
Drug
Lead sponsor
Fernando Fervenza
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 7, 2026, 9:59 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy

NCT01560091
View directory record Official record
Conditions
Kidney Stones
Interventions
silodosin, Extra-corporeal shock wave lithotripsy, Tamsulosin
Drug · Procedure
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 7, 2026, 9:59 PM EDT
Completed Not applicable Interventional

Study to Assess Duration of Indwelling Catheter After Sacrocolpopexy

NCT02189291
View directory record Official record
Conditions
Pelvic Organ Prolapse, Urinary Tract Infections, Urinary Retention
Interventions
Immediate catheter removal, Post op day 1 catheter removal
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 85 Years · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Detroit, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 7, 2026, 9:59 PM EDT
Completed Not applicable Interventional

Laparoscopic Three-dimensional Versus Two-dimensional Sacral Colpopexy and Paravaginal Repair

NCT02258230
View directory record Official record
Conditions
Pelvic Organ Prolapse, Cystocele
Interventions
3D mode of the 3D Laparoscopic Video System, 2D mode of the 3D Laparoscopic Video System
Device
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
18 Years and older · Female only
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Los Angeles, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 7, 2026, 9:59 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

NCT01651000
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
Interventions
CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
Drug · Other
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bannockburn, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 7, 2026, 9:59 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels

NCT05161936
View directory record Official record
Conditions
Recurrent Calcium Oxalate Kidney Stone Disease, Elevated Urinary Oxalate Levels
Interventions
Lumasiran, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
17
States / cities
Birmingham, Alabama • Northridge, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 7, 2026, 9:59 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal Function

NCT04446507
View directory record Official record
Conditions
Renal Impairment
Interventions
Saroglitazar magnesium
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
DeLand, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Oct 7, 2026, 9:59 PM EDT
Completed Phase 3 Interventional Results available

Mycoplasma Genitalium Antibiotic Susceptibility and Treatment (MEGA)

NCT00358462
View directory record Official record
Conditions
Urethritis
Interventions
Azithromycin, Doxycycline
Drug
Lead sponsor
University of Washington
Other
Eligibility
16 Years and older · Male only
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 7, 2026, 9:59 PM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

NCT06059846
View directory record Official record
Conditions
Urinary Tract Infection, Acute Pyelonephritis
Interventions
TBP-PI-HBr, Imipenem-cilastatin, Dummy Infusion, Dummy Tablets
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 7, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer

NCT00378703
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate, Temsirolimus
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
558
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 356 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 7, 2026, 9:59 PM EDT
Completed Not applicable Interventional Results available

Increasing Live Donor Kidney Transplantation Through Video-based Education and Mobile Communication

NCT05154773
View directory record Official record
Conditions
End-stage Renal Disease, Chronic Kidney Diseases
Interventions
Kidney donation and transplant information made easy
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
Not listed
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 7, 2026, 9:59 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

International Registry and Biorepository for TMA(Thrombotic Microangiopathy)

NCT00593229
View directory record Official record
Conditions
Thrombotic Microangiopathy, Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
6 Months to 18 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 7, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

Prospective Randomized Controlled Trial for Pain Relief After Office Ureteral Stent Removal

NCT04112160
View directory record Official record
Conditions
Pain, Urinary Stone, Urinary Calculi
Interventions
Ketorolac, normal saline
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 7, 2026, 9:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Slow Paced-Respiration Intervention to Reduce Incontinence Trial (SPIRIT)

NCT01048424
View directory record Official record
Conditions
Urinary Incontinence, Urge
Interventions
RESPeRATE, Urinary Incontinence Pamphlet
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2013 · Synced Oct 7, 2026, 9:59 PM EDT
Completed Not applicable Interventional

Neurotech Vital Compact Versus Itouch Sure Pelvic Floor Exerciser US

NCT02423005
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Neurotech Vital Compact, itouch Sure Pelvic Floor Exerciser
Device
Lead sponsor
Atlantic Therapeutics
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • Hartford, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 7, 2026, 9:59 PM EDT
Not listed Not applicable Interventional

Assessment of Urinary Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS) Technology in the Evaluation and Management of Females With Chronic Bladder Pain and Cystitis-like Symptoms

NCT05276466
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Polymerase Chain Reaction and Next-Generation DNA Sequencing
Diagnostic Test
Lead sponsor
MicroGenDX
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Los Angeles, California • San Diego, California • Camden, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 7, 2026, 9:59 PM EDT
Completed No phase listed Observational

A Comparison of Physical Activity Levels With and Without Feedback Via Fitbit® Flex™ in Hemodialysis Patients

NCT02320513
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Wearing activty monitoring device (Fitbit Flex), Fitbit Flex
Other · Device
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Oct 7, 2026, 9:59 PM EDT
Not listed Phase 4 Interventional

Vaginal Estrogen for Asymptomatic Microscopic Hematuria

NCT03033160
View directory record Official record
Conditions
Asymptomatic Microscopic Hematuria
Interventions
Estradiol Ring
Drug
Lead sponsor
Boston Urogynecology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 7, 2026, 9:59 PM EDT
Completed Not applicable Interventional Results available

Gut Microbiome and p-Inulin in Hemodialysis

NCT02572882
View directory record Official record
Conditions
End-Stage Renal Disease, Gut Microbiome Dysbiosis
Interventions
p-inulin
Dietary Supplement
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 7, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

Trial of Oral Glutamine on Mitochondrial Function in CKD

NCT02838979
View directory record Official record
Conditions
Cardiovascular Disease, Sarcopenia, Endothelial Dysfunction, Muscle Mitochondrial Function, Kidney Disease
Interventions
First Intervention (14 days), Washout (3 weeks), Second Intervention (14 days)
Dietary Supplement · Other
Lead sponsor
University of Washington
Other
Eligibility
20 Years to 69 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 7, 2026, 9:59 PM EDT